Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3311175 | 1.00 | TDP1 (0.37) | TDP1ALDH1A1KCNH2GRIN2BKDM4E | |
| SCHEMBL169393 | 0.81 | ALDH1A1 (0.42) | TDP1ALDH1A1MGAMGAASI | |
| SCHEMBL13327495 | 0.81 | KCNH2 (0.49) | KCNH2 | |
| SCHEMBL24791075 | 0.81 | FFAR4 (0.38) | TDP1ALDH1A1KDM4EMGAMGAA | |
| SCHEMBL14222881 | 0.79 | KCNH2 (0.33) | KCNH2KMT2A | |
| SCHEMBL2779505 | 0.78 | TDP1 (0.50) | TDP1ALDH1A1MGAMGAASI | |
| SCHEMBL9134377 | 0.78 | TDP1 (0.50) | TDP1ALDH1A1MGAMGAASI | |
| SCHEMBL26914635 | 0.78 | TDP1 (0.50) | TDP1ALDH1A1MGAMGAASI | |
| SCHEMBL25311355 | 0.78 | TDP1 (0.50) | TDP1ALDH1A1MGAMGAASI | |
| SCHEMBL18797 | 0.78 | TDP1 (0.50) | TDP1ALDH1A1MGAMGAASI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2013-01-24 | — | — | US | disclosed |
| EP-2233479-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | Liverpool School of Tropical Medicine (GB) | 2010-09-29 | — | — | EP | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2010-05-06 | — | — | US | disclosed |
| EP-2091935-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | Liverpool School of Tropical Medicine (GB) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
| WO-2008038030-A2 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | LIVERPOOL SCHOOL OF TROPICAL MEDICINE (GB) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113436-A1 | DISPIRO TETRAOXANE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MALARIA AND/OR CANCER | NR1H2, NR1H3, NR1I2 | TDP1 4636/4885ALDH1A1 2379/4885KCNH2 3497/4885 |
| US-20130023551-A1 | DISPIRO TETRAOXANE COMPOUNDS | NR1H3, NR1H2, NR1I2 | TDP1 4380/4885ALDH1A1 2569/4885KCNH2 2334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.